245 related articles for article (PubMed ID: 29044863)
41. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
[TBL] [Abstract][Full Text] [Related]
42. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
[TBL] [Abstract][Full Text] [Related]
43. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract][Full Text] [Related]
44. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
Farah AM; Gu S; Jia Y
Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
46. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
[TBL] [Abstract][Full Text] [Related]
47. Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.
Shin HY; Yang W; Chay DB; Lee EJ; Chung JY; Kim HS; Kim JH
Mol Oncol; 2021 Apr; 15(4):987-1004. PubMed ID: 33331115
[TBL] [Abstract][Full Text] [Related]
48. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
[TBL] [Abstract][Full Text] [Related]
49. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract][Full Text] [Related]
50. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Anglesio MS; Bashashati A; Wang YK; Senz J; Ha G; Yang W; Aniba MR; Prentice LM; Farahani H; Li Chang H; Karnezis AN; Marra MA; Yong PJ; Hirst M; Gilks B; Shah SP; Huntsman DG
J Pathol; 2015 Jun; 236(2):201-9. PubMed ID: 25692284
[TBL] [Abstract][Full Text] [Related]
51. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
Wang Q; Wang L; L Y; Ding X; Liu A
J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
[TBL] [Abstract][Full Text] [Related]
52. Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma.
Yin X; Bi R; Ma P; Zhang S; Zhang Y; Sun Y; Zhang Y; Jing Y; Yu M; Wang W; Tan L; Di W; Zhuang G; Cai MC
J Med Genet; 2020 Sep; 57(9):605-609. PubMed ID: 31862729
[TBL] [Abstract][Full Text] [Related]
53. Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma.
Jung US; Min KW; Kim DH; Kwon MJ; Park H; Jang HS
J Gynecol Oncol; 2021 Jan; 32(1):e3. PubMed ID: 33185044
[TBL] [Abstract][Full Text] [Related]
54. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
55. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium.
Suda K; Nakaoka H; Yoshihara K; Ishiguro T; Tamura R; Mori Y; Yamawaki K; Adachi S; Takahashi T; Kase H; Tanaka K; Yamamoto T; Motoyama T; Inoue I; Enomoto T
Cell Rep; 2018 Aug; 24(7):1777-1789. PubMed ID: 30110635
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.
Maeda D; Mao TL; Fukayama M; Nakagawa S; Yano T; Taketani Y; Shih IeM
Int J Mol Sci; 2010; 11(12):5120-8. PubMed ID: 21614196
[TBL] [Abstract][Full Text] [Related]
57. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
[TBL] [Abstract][Full Text] [Related]
58. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
59. Involvement of Chromatin Remodeling Genes and the Rho GTPases
Arildsen NS; Jönsson JM; Bartuma K; Ebbesson A; Westbom-Fremer S; Måsbäck A; Malander S; Nilbert M; Hedenfalk IA
Front Oncol; 2017; 7():109. PubMed ID: 28611940
[TBL] [Abstract][Full Text] [Related]
60. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
